Search

Search Results

1. Reverse Engineering Drugs: Lorcaserin as an Example

   Novel central nervous system (CNS)-based therapies have been difficult to produce due to the complexity of the brain, limited knowledge of CNS-based...

   Tiffany Schwasinger-Schmidt, Sheldon H. Preskorn in Drug Development in Psychiatry

   Chapter 2023
   

2. Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior

   Serotonin reuptake inhibitors and receptor agonists are used to treat obesity, anxiety and depression. Here we studied the role of the serotonin 2C...

   Yang He, Bas Brouwers, ... I. Sadaf Farooqi in Nature Medicine

   Article Open access 19 December 2022
   

3. Pharmacotherapy of Obesity

   Obesity accounts for 0.3 million and 2.8 million deaths/year, respectively, in South East Asia and worldwide and globally its prevalence triples from...

   Mageshwaran Lakshmanan in Introduction to Basics of Pharmacology and Toxicology

   Chapter 2021
   

4. Nanotechnology in the Context of Obesity

   Obesity is a pandemic disease with immense magnitude and it is due to escalating death with co-morbidity in this century. Obesity is caused by...

   Satheesh Babu Natarajan, Suriyakala Perumal Chandran, Methil Kannan Kutty in Obesity and its Impact on Health

   Chapter 2021
   

5. Lennox-Gastaut Syndrome: Current Treatments, Novel Therapeutics, and Future Directions

   Lennox-Gastaut syndrome is a severe drug-resistant developmental and epileptic encephalopathy with slow spike and wave on EEG (DEE-SSW) composing...

   Julie A. Nelson, Kelly G. Knupp in Neurotherapeutics

   Article 23 June 2023

6. Serotonin 2C receptors are also important in head-twitch responses in male mice

   Rationale

   Serotonergic psychedelics exert their effects via their high affinity for serotonin (5-HT) receptors, particularly through activating 5-HT2A...

   Raly James Perez Custodio, Darlene Mae Ortiz, ... Hee ** Kim in Psychopharmacology

   Article 26 October 2023
   

7. Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis

   Purpose

   Anti-obesity therapy can reduce body weight; however, it is not clear whether it can reduce major adverse cardiovascular events (MACEs). We...

   Lin Zhang, Zhi Liu, ... Mei Zhang in European Journal of Clinical Pharmacology

   Article 27 May 2021
   

8. Gut Microbiome and Obesity: Connecting Link

   Obesity is a worldwide epidemic with unknown etiology. It is now accepted as a state of chronic low-grade inflammation. Several genetic and...

   Jayshree Mishra, Khyati Amin, ... Narendra Kumar in Microbial Engineering for Therapeutics

   Chapter 2022
   

9. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development

   Based extensively on tables and figures, this chapter reviews drug development in psychiatry with an emphasis on antidepressants from the 1950s to...

   Sheldon H. Preskorn in Drug Development in Psychiatry

   Chapter 2023
   

10. Synergistic Herb-Drug Interactions Against Obesity

    Obesity is a long-term lifestyle problem that can lead to several ailments and disastrous consequences. Lifestyle interventions are one of the...

    Shanmugam Hemaiswarya, Pranav Kumar Prabhakar, Mukesh Doble in Herb-Drug Combinations

    Chapter 2022
    

11. Anti-obesity Drugs

    Christine Huppertz in Encyclopedia of Molecular Pharmacology

    Reference work entry 2021
    

12. Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity

    The epidemic structure of obesity has known to exacerbate or initiate comorbidities, including cardiovascular complications and diabetes. Although...

    Bapi Gorain, Hira Choudhury, ... Manisha Pandey in Obesity and its Impact on Health

    Chapter 2021
    

13. Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity

    Stephanie W. Waldrop, Veronica R. Johnson, Fatima Cody Stanford in Nature Medicine

    Article 03 January 2024
    

14. Back to the Future of Neuropsychopharmacology

    Disappointments in translating preclinical findings into clinical efficacy have triggered a number of changes in neuroscience drug discovery ranging...

    Anton Bespalov, Marcel van Gaalen, Thomas Steckler in Drug Development in Psychiatry

    Chapter 2023
    

15. Therapeutics in Metabolic Diseases

    Metabolic diseases have important effects on the health and healthcare costs of an individual. It adversely affects various body processes. Metabolic...

    Vijayakumar Natesan in Genome Editing in Cardiovascular and Metabolic Diseases

    Chapter 2023
    

16. A MIST conception: what has been learned from twenty years of human metabolite safety assessment?

    In this review, we trace origins of the joint initiative of the pharmaceutical industry and major regulatory authorities to provide a framework for...

    Debra Luffer-Atlas, R. Scott Obach, Dennis A. Smith in Medicinal Chemistry Research

    Article 13 June 2023
    

17. Caffeine: a potential mechanism for anti-obesity

    Obesity refers to the excessive accumulation of fat caused by a long-term imbalance between energy intake (EI) and energy expenditure (EE). Over...

    Meng Wang, Wei Guo, Jiang-Fan Chen in Purinergic Signalling

    Article 28 May 2024
    

18. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

    Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and potentially permanent side effect of cancer treatment. For...

    Yang Yang, Bing Zhao, ... Peng Cao in Journal of Experimental & Clinical Cancer Research

    Article Open access 22 October 2021
    

19. Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Current Clinical Data and Future Directions

    Chemotherapy-induced peripheral neurotoxicity (CIPN) is a treatment related toxicity that burdens the quality of life of cancer survivors....

    Paola Alberti, Christopher B. Steer in Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy

    Chapter 2021
    

20. Cannabinoids: an Effective Treatment for Chemotherapy-Induced Peripheral Neurotoxicity?

    Chemotherapy-induced peripheral neurotoxicity (CIPN) is one of the most frequent side effects of antineoplastic treatment, particularly of lung,...

    Guido Cavaletti, Paola Marmiroli, ... Cristina Meregalli in Neurotherapeutics

    Article Open access 19 October 2021